Merck & Co. Inc., MRK is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in USA, Merck & Co. Inc., MRK has a market cap of 158950.85. Since its IPO date on the 1/2/1970, Merck & Co. Inc., MRK performance year to date is 11.00%. Today Merck & Co. Inc., MRK has gained 0.26%, with a current price of 57.8.
Ownership of the company is 0.04% for insider ownership while institutional ownership is 75.00%. The management of the company have seen the company have a payout ratio of 74.60%. Return of assets are at *TBA, with return on investment at 6.40%.
In terms of debt levels and profit levels, Merck & Co. Inc., MRK is seeing a long-term debt/equity of *TBA. While Total debt/equity is *TBA. With a profit margin of 13.00%, this is combined with a gross margin of 62.80%, and operating margin of 18.10%. Merck & Co. Inc. ability to meet debt levels, with a current ratio of *TBA, while the quick ratio is *TBA.
For the last year Merck & Co. Inc., MRK has seen a EPS growth of -61.60%. A performance for the year of 1.61%. The 52-week high is -3.59%, and the 52-week low is 30.88%. The average volume for Merck & Co. Inc., MRK is 2329771.
With a target price of 62.05, can Merck & Co. Inc., MRK reach this target? Looking at the value indicators of Merck & Co. Inc., MRK. Merck & Co. Inc. has a P/E of 35.26 and a forward P/E of 15.38. Perhaps the more useful indicator than P/E, is PEG which has a value of 6.77. Merck & Co. Inc. also has a P/S and a P/B of 4.04 and 3.64 respectively. For P/cash, Merck & Co. Inc. has a value of *TBA, while it is *TBA for P/free cash flow.
At the current price of 57.8, Merck & Co. Inc. has a dividend yield of 3.19%. We see a return on equity of *TBA.
Looking more long-term Merck & Co. Inc., is projected to get an EPS growth for the next five years of 5.21%. In the short-term an EPS growth of 0.78% in the next year is forecasted. This is after a EPS growth of -61.60% for this year and for the last five years a 41.50% growth has been seen.